A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

You may be able to join this study if you are 60 years old or older and have geographic atrophy caused by dry AMD. The study team will measure your vision and take detailed pictures of the back of your eye to make sure the damaged area meets the trial's exact size requirements.

You will not be eligible if your vision problems are caused by another eye condition or by 'wet' AMD, which involves leaking blood vessels. People who have had injections for wet AMD in the study eye cannot take part.

You will also be excluded if you have had a recent eye infection, uncontrolled glaucoma, eye inflammation such as uveitis, or certain prior treatments like eye steroids, laser therapy to the macula, or gene therapy. A trial doctor will carefully review your full medical history to confirm if joining is safe for you.

If you take part, you will receive a single treatment in the study eye. Depending on which group you are in, this will either be the active medicine or a 'sham' procedure. A sham procedure mimics an injection by applying light pressure to the eye, but no needle goes into the eye and no medicine is given.

The main study lasts around two years, followed by an extended follow-up phase of three years, making five years in total. You will need to attend regular clinic appointments so the medical team can test your vision, take detailed scans of your retina, and check your overall health. These frequent visits help doctors spot any side effects early and see how your eye responds over time.